Bio-Thera starts Phase 1 dosing for BAT8013 CD25-targeting ADC

The open-label study in advanced solid tumors will assess safety, tolerability, pharmacokinetics and preliminary efficacy while seeking a maximum tolerated dose and recommended Phase 2 dose.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.